A diagnostic leader in personalized onco-medicine

Providing High-Quality Gene Expression Prognostic & Predictive Services for the Personalized Medicine
arena to Enable Better Management of Cancer Patients


Management Team

Emmanuel Zachariah, Ph.D.
President & Chief Executive Officer

Dr. Zachariah began his postdoctoral training in Microarrays and Microfluidics fields at The National University of Singapore and has voluminous background in Microarrays, Microfluidics, Biosensors, Immunodiagnostics, Cancer research and personalized medicine.  Creatively integrating technologies from diverse fields and transforming these elements into world class product solutions is his specialty. For the past 5 years he has developed several Focused microarrays for pathway analyses. Recent accomplishments include innovations for the Neutraceutical screening method for WellGen. Dr. Zachariah also was a founding member of Biosensor Focused Interest Group, Singapore in 2001, and pioneered the application of microfluidic devices for the biological applications such as Polymerase chain reaction (PCR), DNA extraction, micro Capillary Electrophoretic (CE) separation and Lab on Chip. Earlier research and development on the Biosensors at National University of Singapore resulted in development of various Biosensors. He established first microarray facility at the National University of Singapore during 1998. Three United States Patents have been issued to Dr. Zachariah to date. Another two patent applications  on personalized cancer medicine is currently being prosecuted in the United States.

Harun Sevimli, MBA
Director, International Business Development

Mr. Sevimli has extensive experience in international trade, consulting, financing, and marketing. He is multi national and multi lingual. He has owned companies in Germany, Turkey and in the U.S. and handled logistics for WFP/U.N. for the Food Bank in Northern Iraq. His latest company, Amerturk, Inc, a full service asset management partner for electronics retailers and wholesalers includes several Fortune 500 companies for customers. Mr. Sevimli brings his skills in international trade to the Consumer Genetics product line. He has helped to established partners in more than 33 countries since the end of 2008. Mr. Sevimli has a degree in finance.